Novo Nordisk stock is paring its year-over-year deficit on positive early stage trial results for the company's new weight ...

Novo Nordisk’s NVO shares gained 8.5% on Friday after the company announced positive top-line data from an early to mid-stage ...

Novo Nordisk stock gains as its subcutaneous investigational candidate, amycretin, achieves superior weight loss compared to ...

Amycretin could give Novo a buzzy product in a newly competitive obesity market. It works similarly to existing GLP-1 ...

The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Now the key question is: Where could the stock be headed in the near term ... has resulted in a Zacks Rank #3 (Hold) for Novo Nordisk. The chart below shows the evolution of the company's forward ...

Novo Nordisk is facing serious pressure from a powerful ... Let's investigate what's going on and whether the stock is still worth buying for a long-term hold. The bull thesis isn't what it ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

I'm going to break down why a recent piece of news from Novo Nordisk caused the stock to tank. Moreover, I'll explore if now is an opportunity to buy the dip, or run for the hills. On Dec. 20 ...

Novo Nordisk presents a compelling 'Strong Buy ... but also creates the basis for future growth. The below chart suggests that innovation has consistently been the core of NVO's long-term strategy ...